Despite consistent side effects for Navitoclax, which included thrombocytopenia, based on Bcl-xL expression-dependency for platelet survival, it was effective at killing Bcl-2-dependent CLL cancers, just as effectively as ABT-737 [138]. The gene discussed is BCL2; the disease is Thrombocytopenia.